Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-centre, Multi-national, Comparative, Randomised, Cross-over Trial Evaluating Preference as Well as Performance, Acceptance, Handling and Safety of NovoPen™ 4 (MS236) Versus NovoPen 3® in Insulin Treated Diabetic Patients

NCT00569998 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00569998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00569998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-centre, Multi-national, Comparative, Randomised, Cross-over Trial Evaluating Preference as Well as Performance, Acceptance, Handling and Safety of NovoPen™ 4 (MS236) Versus NovoPen 3® in Insulin Treated Diabetic Patients
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2003
Completion date
February 29, 2004
Enrollment
208 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

delivery systems, diabetes, diabetes mellitus, type 1, diabetes mellitus, type 2